drugset / Trial / NCT03871855
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination with Camrelizumab among advanced solid tumor subjects.
Timeline
- Start
- 2019-04-28
- Primary completion
- 2021-06-21
- Completion
- 2021-06-21
Outcome
Outcome not reported
Stopped (Business): “Sponsor R \& D Strategy Adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | Intravenous |
| Subject | SHR-1702 | Unknown | — | Intravenous |